Wells Fargo’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-56,101
| Closed | -$1.35M | – | 7792 |
|
|
2023
Q1 | $1.35M | Sell |
56,101
-3,747
| -6% | -$47K | ﹤0.01% | 3163 |
|
|
2022
Q4 | $633K | Buy |
59,848
+54,688
| +1,060% | +$441K | ﹤0.01% | 3503 |
|
|
2022
Q3 | $23K | Sell |
5,160
-367
| -7% | -$1.67K | ﹤0.01% | 5333 |
|
|
2022
Q2 | $22K | Sell |
5,527
-4,117
| -43% | -$19.5K | ﹤0.01% | 5417 |
|
|
2022
Q1 | $71K | Sell |
9,644
-20,656
| -68% | -$124K | ﹤0.01% | 5489 |
|
|
2021
Q4 | $170K | Buy |
30,300
+18,904
| +166% | +$120K | ﹤0.01% | 5359 |
|
|
2021
Q3 | $73K | Sell |
11,396
-13,687
| -55% | -$88K | ﹤0.01% | 5500 |
|
|
2021
Q2 | $212K | Sell |
25,083
-1,739
| -6% | -$14K | ﹤0.01% | 5008 |
|
|
2021
Q1 | $281K | Sell |
26,822
-26,186
| -49% | -$368K | ﹤0.01% | 5002 |
|
|
2020
Q4 | $898K | Buy |
53,008
+18,791
| +55% | +$282K | ﹤0.01% | 4106 |
|
|
2020
Q3 | $439K | Sell |
34,217
-12,041
| -26% | -$152K | ﹤0.01% | 4442 |
|
|
2020
Q2 | $652K | Buy |
46,258
+6,486
| +16% | +$81.9K | ﹤0.01% | 4136 |
|
|
2020
Q1 | $366K | Sell |
39,772
-13,185
| -25% | -$170K | ﹤0.01% | 4269 |
|
|
2019
Q4 | $788K | Buy |
52,957
+36,957
| +231% | +$329K | ﹤0.01% | 4020 |
|
|
2019
Q3 | $109K | Hold |
16,000
| – | – | ﹤0.01% | 5280 |
|
|
2019
Q2 | $194K | Buy |
+16,000
| New | +$87.1K | ﹤0.01% | 4995 |
|
Other funds holding PRVB
Wells Fargo's PRVB Position: Q2 2023 in Review
Wells Fargo sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 56,101 shares — an estimated $1.35M sold.
Wells Fargo first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $1.35M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Wells Fargo reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 56,101 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.35M.
- Wells Fargo first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Wells Fargo's Provention Bio, Inc. Common Stock position peaked at $1.35M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.